Compare LNZA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNZA | CERS |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | 192 | N/A |
| Industry | Major Chemicals | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.8M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | LNZA | CERS |
|---|---|---|
| Price | $22.12 | $2.57 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 2.3M |
| Earning Date | 05-18-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $55.80 | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $0.19 | $1.15 |
| 52 Week High | $44.00 | $3.15 |
| Indicator | LNZA | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 68.72 |
| Support Level | $22.08 | $1.84 |
| Resistance Level | $29.51 | $2.68 |
| Average True Range (ATR) | 3.12 | 0.17 |
| MACD | -1.00 | 0.08 |
| Stochastic Oscillator | 5.56 | 55.38 |
LanzaTech Global Inc is a provider of carbon management and conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical industrial inputs. Its mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging scalable biotechnology solutions to maximize the value of domestic resources. The company operates in North America, Europe, the Middle East, Africa (EMEA), Asia, and Australia, with the majority of its revenue generated from North America.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.